establish safety and efficacy and may cause harms.

The FDA submitted an "Interim Access Policy" on peptides for review by the White House, according to a filing notice posted on an Office of Management and Budget website. The posting does not provide information on the proposed policy. But people familiar with the proposal told The Associated Press that it would give the FDA "enforcement discretion" on certain peptide drugs. This would allow the agency to choose not to enforce current restrictions on peptides and provide an assurance to specialty pharmacies eager to start making them that they will not be targeted by the agency.

The Department of Health and Human Services, which oversees the FDA, did not respond to a request for comment from Ars Technica.

Comments

28:T426,{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://nvdium.com/en/articles/473581906#article","url":"https://nvdium.com/en/articles/473581906","headline":"RFK Jr. proposes FDA look the other way on unproven peptides, report says","description":"FDA scientists said none of the popular drugs have been proven safe or effective.","datePublished":"2026-10-16T18:44:29.834Z","dateModified":"2026-10-18T20:25:28.977Z","mainEntityOfPage":"https://nvdium.com/en/articles/473581906","isAccessibleForFree":true,"inLanguage":"en","isPartOf":{"@id":"https://nvdium.com/#website"},"speakable":{"@type":"SpeakableSpecification","cssSelector":[".article-header h1","[data-testid='article-summary']"]},"articleSection":"Technology","keywords":"","image":["https://nvdium.com/nvdium-logo.png"],"author":[{"@type":"Person","name":"Beth M